Tasly Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.taslyus.com
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT02388984
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of TCM, Guang Zhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangxi Medical University, Nan Ning, Guangxi, China
🇨🇳Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Bei Jing, Beijing, China
Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2014-11-24
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01679028
- Locations
- 🇺🇸
California Clinical Trial Medical Group, Glendale, California, United States
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
- Conditions
- Interventions
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 1004
- Registration Number
- NCT01659580
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸Beaver Medical Clinic, Banning, California, United States
🇺🇸NewPhase Clinical Trials, Inc., Miami Beach, Florida, United States
Phase III Study of 5LGr to Treat Tic Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT01501695
A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin
- Conditions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01475279
- Locations
- 🇺🇸
Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States
A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01473888
- Locations
- 🇺🇸
Comprehensive Clinical Development NW Inc., Tacoma, Washington, United States
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Tasly Pharmaceuticals, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT00797953
- Locations
- 🇺🇸
Three Rivers Medical Associates, Columbia, South Carolina, United States
🇺🇸East Texas Cardiology, Houston, Texas, United States
🇺🇸Northwest Heart Center, Tomball, Texas, United States